Recurrent cutaneous hyalohyphomycosis secondary to Purpureocillium lilacinum in an immunocompetent individual

Australas J Dermatol. 2021 Aug;62(3):e411-e413. doi: 10.1111/ajd.13657. Epub 2021 Jun 25.

Abstract

Purpureocillium lilacinum, previously classified as Paecilomyces lilacinus, is a ubiquitous hyaline hyphomycete considered to be an emerging opportunistic human pathogen that is resistant to traditional antifungal agents. This case report describes what is to our knowledge the only published case of P. lilacinum recrudescence in an immunocompetent host despite initial best-practice treatment with 10 weeks of voriconazole and surgical excision.

Keywords: Paecilomyces lilacinus; Purpureocillium lilacinum; anti fungal agents; cutaneous hyalohyphomycosis; dermatology; human; immunocompetent; posaconazole; voriconazole.

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Dermatomycoses / drug therapy*
  • Dermatomycoses / microbiology
  • Humans
  • Hyalohyphomycosis / drug therapy*
  • Hyalohyphomycosis / microbiology
  • Hypocreales / isolation & purification*
  • Recurrence

Substances

  • Antifungal Agents

Supplementary concepts

  • Purpureocillium lilacinum